Search

Your search keyword '"Henter, Jan‐Inge"' showing total 1,001 results

Search Constraints

Start Over You searched for: Author "Henter, Jan‐Inge" Remove constraint Author: "Henter, Jan‐Inge"
1,001 results on '"Henter, Jan‐Inge"'

Search Results

1. Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF

2. Etoposide Therapy of Cytokine Storm Syndromes

4. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

5. Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation

7. High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19

9. Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity

10. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis

11. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

15. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

16. Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation

18. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults

19. Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients

22. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

24. Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation

26. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

29. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

31. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

33. Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy

36. The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis

37. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis

38. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

40. The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis

41. HYPERINFLAMMATION IN CRITICALLY ILL PATIENTS IN INTENSIVE CARE

42. Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.

43. Myeloid cells from Langerhans cell histiocytosis patients exhibit increased vesicle trafficking and an altered secretome capable of activating NK cells

46. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

47. Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology

50. The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis.

Catalog

Books, media, physical & digital resources